The efficacy of topical therapy with cream containing ivermectin 1% is out of question. There is an improvement in the symptoms of various types of rosacea after the start of its use. Sometimes topical therapy alone is not enough to develop sustained remission without the acute conditions in patients after the conducted treatment with the use of pulsed dye laser.

OBJECTIVE

To evaluate the use of dermal bioreparant with trehalosa as a part of combined treatment in preparation for laser therapy.

MATERIAL AND METHODS

In the Estelab clinic 56 patients, 53 women and 3 men aged from 35 to 64 years with rosacea diagnosis (ICD-10: L71.1-9) were monitored. They were admitted with complaints of flushes, redness of the skin in the central face area of the erythematous telangiectatic and papulopustular subtypes of rosacea, which met the inclusion and exclusion criteria. Patients, divided into 3 groups, were given a combined treatment protocol with ivermectin 1% in conjunction with the use of pulsed dye laser and injections of dermal biopharmaceutical based on hyaluronic acid and REVI trehalose. Injections were added to the treatment protocol at various stages in different groups.

RESULTS

The combined rosacea treatment protocol was most effective in patients of the 2nd group, who had the improved rosacea symptoms after the initial topical therapy with ivermectin 1%, as well as in patients of the 1st and 3rd (control) groups. After the third stage of treatment, which contained the application of laser procedure with the use of pulsed dye laser, no cases of acute condition and symptoms worsening were revealed in patients of the 2nd group.

CONCLUSION

The use of dermal bioreparant with trehalose in preparation for laser therapy with the use of pulsed dye laser in the combined protocol allowed to achieve sustained remission, avoid adverse events in the form of worsening of rosacea manifestations and therefore improve the patients’ quality of life.